Table 2.
Comparison of craniocervical flexion test and 8 domains of SF 36 within the control group.
| Variable | — | Interquartile range | Mean ranka | Chi-square (X2), p valuea | Post hoc analysis | Z scoreb | p valueb |
|---|---|---|---|---|---|---|---|
| Craniocervical flexion (mmHg) | Base line | 22 (20 to 24) | 1.18 | 68.70, p < 0.05 | Pre and midtreatment | -5.26 | <0.017 |
| After 2nd week | 23 (22 to 26) | 2.09 | Mid and posttreatment | -4.66 | <0.017 | ||
| After 4th week | 24 (24 to 26) | 2.73 | Pre and posttreatment | -5.53 | <0.017 | ||
| Physical functioning–SF36 | Baseline | 40 (21.25 to 55) | 1.41 | 54.25, p < 0.05 | Pre and midtreatment | -3.17 | 0.001 |
| After 2nd week | 52.5 (30 to 65) | 1.86 | Mid and posttreatment | -5.03 | <0.017 | ||
| After 4th week | 70 (45 to 80) | 2.73 | Pre and posttreatment | -4.66 | <0.017 | ||
| Role limitation due to physical health–SF36 | Baseline | 0 (0 to 0) | 1.63 | 37.90, p < 0.05 | Pre and midtreatment | -2.55 | 0.011 |
| After 2nd week | 0 (0 to 25) | 1.88 | Mid and posttreatment | -4.11 | <0.017 | ||
| After 4th week | 50 (0 to 75) | 2.50 | Pre and posttreatment | -4.45 | <0.017 | ||
| Role limitation due to emotional problem–SF36 | Baseline | 16.65 (0 to 66.70) | 1.88 | 17.03, p < 0.05 | Pre and midtreatment | -1.41 | 0.157 |
| After 2nd week | 16.65 (0 to 66.70) | 1.92 | Mid and posttreatment | -2.75 | <0.017 | ||
| After 4th week | 66.70 (0 to 100) | 2.20 | Pre and posttreatment | -2.88 | <0.017 | ||
| Energy/fatigue–SF36 | Baseline | 42.5 (35 to 50) | 1.42 | 48.42, p < 0.05 | Pre and midtreatment | -4.01 | <0.017 |
| After 2nd week | 45 (36.25 to 55) | 1.94 | Mid and posttreatment | -4.47 | <0.017 | ||
| After 4th week | 55 (45 to 63.75) | 2.64 | Pre and posttreatment | -4.93 | <0.017 | ||
| Emotional wellbeing–SF36 | Baseline | 52 (40 to 56) | 1.61 | 27.22, p < 0.05 | Pre and midtreatment | -2.64 | <0.017 |
| After 2nd week | 52 (40 to 60) | 1.92 | Mid and posttreatment | -4.04 | <0.017 | ||
| After 4th week | 60 (48 to 60) | 2.47 | Pre and posttreatment | -4.13 | <0.017 | ||
| Social functioning–SF36 | Baseline | 50 (37.5 to 62.5) | 1.63 | 35.89, p < 0.05 | Pre and midtreatment | -2.44 | 0.015 |
| After 2nd week | 50 (37.5 to 62.5) | 1.85 | Mid and posttreatment | -4.37 | <0.017 | ||
| After 4th week | 62.5 (50 to 75) | 2.52 | Pre and posttreatment | -4.45 | <0.017 | ||
| Pain–SF36 | Baseline | 45 (45 to 45) | 1.45 | 54.60, p < 0.05 | Pre and midtreatment | -3.37 | <0.017 |
| After 2nd week | 45 (45 to 67.5) | 1.83 | Mid and posttreatment | -4.45 | <0.017 | ||
| After 4th week | 55 (55 to 77.5) | 2.72 | Pre and posttreatment | -5.13 | <0.017 | ||
| General health perception–SF36 | Base line | 35 (31.25 to 45) | 1.41 | 51.95, p < 0.05 | Pre and midtreatment | -3.64 | <0.017 |
| After 2nd week | 40 (35 to 50) | 1.92 | Mid and posttreatment | -4.58 | <0.017 | ||
| After 4th week | 47.5 (40 to 60) | 2.67 | Pre and posttreatment | -5.01 | <0.017 |